| 4.75 0 (0%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.19 | 1-year : | 8.66 |
| Resists | First : | 6.15 | Second : | 7.42 |
| Pivot price | 5.46 |
|||
| Supports | First : | 4.11 | Second : | 3.42 |
| MAs | MA(5) : | 4.69 |
MA(20) : | 5.65 |
| MA(100) : | 4.48  |
MA(250) : | 2.75 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.9 |
D(3) : | 19 |
| RSI | RSI(14): 42.2 | |||
| 52-week | High : | 7.42 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALRN ] has closed above bottom band by 19.8%. Bollinger Bands are 40.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5 - 5.03 | 5.03 - 5.05 |
| Low: | 4.45 - 4.48 | 4.48 - 4.51 |
| Close: | 4.7 - 4.75 | 4.75 - 4.79 |
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Thu, 18 Apr 2024
Aileron Therapeutics sharestarget doubled by Ladenburg Thalmann - Investing.com India
Thu, 18 Apr 2024
Aileron Therapeutics, Inc. (ALRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Movies Canada
Tue, 16 Apr 2024
Aileron Therapeutics GAAP EPS of -$1.54 misses by $1.37 - Seeking Alpha
Fri, 29 Mar 2024
Aileron Therapeutics Announces CFO Transition and Appointment - TipRanks
Tue, 12 Mar 2024
Aileron Therapeutics Announces CEO Transition - Yahoo Finance
Thu, 29 Feb 2024
Aileron Therapeutics' Shareholders Approve Major Stock Proposals - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 18.1 (%) |
| Shares Short | 35 (K) |
| Shares Short P.Month | 38 (K) |
| EPS | -3.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -15 % |
| Return on Equity (ttm) | -27 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.9 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -1.39 |
| PEG Ratio | -3.9 |
| Price to Book value | 3.36 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|